Rational Approach to an Antiprion Compound with a Multiple Mechanism of Action

References

• Prusiner SB . Molecular biology of prion diseases. Science252 (5012), 1515–1522 (1991).
   PubMed Web of Science ®Google Scholar
• Winklhofer KF , TatzeltJ, HaassC. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J.27 (2), 336–349 (2008).
   PubMed Web of Science ®Google Scholar
• Prusiner SB . Cell biology. A unifying role for prions in neurodegenerative diseases. Science336 (6088), 1511–1513 (2012).
   PubMed Web of Science ®Google Scholar
• Ashe KH , AguzziA. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion7 (1), 55–59 (2013).
   PubMed Web of Science ®Google Scholar
• Chen B , ThompsonM, LouthJ, GuoK. Prion chemical biology: on the road to therapeutics?Curr. Top Med. Chem.13 (19), 2441–2464 (2013).
   PubMed Web of Science ®Google Scholar
• Geschwind MD , KuoAL, WongKSet al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology81 (23), 2015–2023 (2013).
   PubMed Web of Science ®Google Scholar
• Stoilova T , ColomboL, ForloniG, TagliaviniF, SalmonaM. A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J. Med. Chem.56 (15), 5987 (2013).
   PubMed Web of Science ®Google Scholar
• Forloni G , SalmonaM, MarconG, TagliaviniF. Tetracyclines and prion infectivity. Infect. Disord. Drug. Targets.9 (1), 23–30 (2009).
   PubMedGoogle Scholar
• Forloni G , IussichS, AwanTet al. Tetracyclines affect prion infectivity. Proc. Natl Acad. Sci. USA99 (16), 10849–10854 (2002).
   PubMed Web of Science ®Google Scholar
• Haik S , MarconG, MalletAet al. Doxycycline in Creutzfeldt-Jakob disease: a Phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol.13 (2), 150–158 (2014).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML , LegnameG. Approaches for discovering antiprion compounds: lessons learned and challenges ahead. Expert Opin. Drug Discov.10 (4), 389–97 (2015).
   PubMed Web of Science ®Google Scholar
• Gaggelli E , KozlowskiH, ValensinD, ValensinG. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem. Rev.106 (6), 1995–2044 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DR , GuantieriV, GrassoG, ImpellizzeriG, PappalardoG, RizzarelliE. Copper(II) complexes of peptide fragments of the prion protein. Conformation changes induced by copper(II) and the binding motif in C-terminal protein region. J. Inorg. Biochem.98 (1), 133–143 (2004).
   PubMed Web of Science ®Google Scholar
• Lehmann S . Metal ions and prion diseases. Curr. Opin. Chem. Biol.6 (2), 187–192 (2002).
   PubMed Web of Science ®Google Scholar
• Gasperini L , MeneghettiE, PastoreB, BenettiF, LegnameG. Prion protein and copper cooperatively protect neurons by modulating nmda receptor through S-nitrosylation. Antioxid. Redox Sign.22 (9), 772–784 (2015).
   PubMed Web of Science ®Google Scholar
• Singh N , SinghA, DasD, MohanML. Redox control of prion and disease pathogenesis. Antioxid. Redox Sign.12 (11), 1271–1294 (2010).
   PubMed Web of Science ®Google Scholar
• Soto C , SataniN. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol. Med.17 (1), 14–24 (2010).
   Web of Science ®Google Scholar
• Cavalli A , BolognesiML, MinariniAet al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem.51 (3), 347–372 (2008).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML . Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem.20 (13), 1639–1645 (2013).
   PubMed Web of Science ®Google Scholar
• Bongarzone S , StaderiniM, BolognesiML. Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Med. Chem.6 (9), 1017–1029 (2014).
   PubMed Web of Science ®Google Scholar
• Morphy R . Selective multitargeted drugs. In : Polypharmacology in Drug Discovery. PetersJ-U ( Ed.). John Wiley & Sons, Inc., NJ, USA, 245–262 (2012).
   Google Scholar
• Morphy JR , HarrisCJ. Designing Multi-Target Drugs. Royal Society of Chemistry, RSC drug discovery, Cambridge, UK (2012).
   Google Scholar
• Bongarzone S , BolognesiML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin. Drug Discov.6 (3), 251–268 (2011).
   PubMed Web of Science ®Google Scholar
• Torrent J , Vilchez-AcostaA, Munoz-TorreroDet al. Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases. Acta Neuropathol. Commun.3 (1), 18 (2015).
   PubMedGoogle Scholar
• Prachayasittikul V , PrachayasittikulS, RuchirawatS, PrachayasittikulV. 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des. Devel. Ther.7, 1157–1178 (2013).
   PubMed Web of Science ®Google Scholar
• Cherny RA , AtwoodCS, XilinasMEet al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron30 (3), 665–676 (2001).
   PubMed Web of Science ®Google Scholar
• Ritchie CW , BushAI, MackinnonAet al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol.60 (12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• LeVine H, 3rd, DingQ, WalkerJA, VossRS, Augelli-SzafranCE. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1–42) oligomer assembly. Neurosci. Lett.465 (1), 99–103 (2009).
   PubMed Web of Science ®Google Scholar
• Adlard PA , ChernyRA, FinkelsteinDIet al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron59 (1), 43–55 (2008).
   PubMed Web of Science ®Google Scholar
• Gal S , FridkinM, AmitT, ZhengH, YoudimMB. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural. Transm.70 (Suppl.), 447–456 (2006).
   Google Scholar
• Pollera C , LucchiniB, FormentinE, BareggiS, PoliG, PontiW. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet. Res. Commun.29 (Suppl. 2), 253–255 (2005).
   PubMedGoogle Scholar
• Song Yn , XuH, ChenW, ZhanP, LiuX. 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. Med. Chem. Comm.6 (1), 61–74 (2015).
   Google Scholar
• Fernandez-Bachiller MI , PerezC, Gonzalez-MunozGCet al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem.53 (13), 4927–4937 (2010).
   PubMed Web of Science ®Google Scholar
• Antequera D , BolosM, SpuchCet al. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on a beta accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol. Dis.46 (3), 682–691 (2012).
   PubMed Web of Science ®Google Scholar
• Bongarzone S , TranHN, CavalliAet al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J. Med. Chem.53 (22), 8197–8201 (2010).
   PubMed Web of Science ®Google Scholar
• Bongarzone S , TranHN, CavalliAet al. Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. Chem. Med. Chem.6 (4), 601–605 (2011).
   Google Scholar
• Natarajan JK , AlumasaJN, YearickKet al. 4-N-, 4-S-, and 4-O-chloroquine analogues: influence of side chain length and quinolyl nitrogen pKa on activity vs chloroquine resistant malaria. J. Med. Chem.51 (12), 3466–3479 (2008).
   PubMed Web of Science ®Google Scholar
• May BC , FafarmanAT, HongSBet al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. USA100 (6), 3416–3421 (2003).
   PubMed Web of Science ®Google Scholar
• Tran HN , BongarzoneS, CarloniP, LegnameG, BolognesiML. Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. Bioorg. Med. Chem. Lett.20 (6), 1866–1868 (2010).
   PubMed Web of Science ®Google Scholar
• Bolognesi ML , Ai TranHN, StaderiniMet al. Discovery of a class of diketopiperazines as antiprion compounds. Chem. Med. Chem.5 (8), 1324–1334 (2010).
   Google Scholar
• Staderini M , AulićS, BartoliniMet al. A Fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer's and prion diseases. ACS Med. Chem. Lett.4 (2), 225–229 (2012).
   PubMed Web of Science ®Google Scholar
• Colby DW , ZhangQ, WangSet al. Prion detection by an amyloid seeding assay. Proc. Natl Acad. Sci. USA104 (52), 20914–20919 (2007).
   PubMed Web of Science ®Google Scholar
• Milhavet O , McMahonHE, RachidiWet al. Prion infection impairs the cellular response to oxidative stress. Proc. Natl Acad. Sci. USA97 (25), 13937–13942 (2000).
   PubMed Web of Science ®Google Scholar
• Petersen RB , SiedlakSL, LeeHGet al. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol.110 (3), 232–238 (2005).
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S , AhnM, LessardPet al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog.5 (11), e1000673 (2009).
   PubMed Web of Science ®Google Scholar